当前位置:药药网 / 数据中心 / 生物制药海外临床研究状况
Tomivosertib With Anti-PD-(L)1 in Subjects With NSCLC. 1st Line Therapy or Progressing on 1st Line Anti-PD-(L)1 Therapy
标题(英文)
Tomivosertib With Anti-PD-(L)1 in Subjects With NSCLC. 1st Line Therapy or Progressing on 1st Line Anti-PD-(L)1 Therapy
条件
Non-small Cell Lung Cancer
干预
Drug: Tomivosertib|Biological: Pembrolizumab